Ruxolitinib
| CAS No. | 941678-49-5 |
|---|---|
| MDL No. | MFCD12031592 |
| MF | C17H18N6 |
| MW | 306.40 |
| InChI Key | HFNKQEVNSGCOJV-OAHLLOKOSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Ruxolitinib is a pyrazole substituted at position 1 with a 2-cyano-1-cyclopentylethyl group and at position 3 with a pyrrolo[2,3-d]pyrimidin-4-yl group. It is used as the phosphate salt in the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It functions as an antineoplastic agent and a non-specific protein-tyrosine kinase inhibitor (EC 2.7.10.2). It is a nitrile, a pyrrolopyrimidine, and a member of pyrazoles.
| CAS No. | 941678-49-5 |
|---|---|
| Product Name | Ruxolitinib |
Biological Targets
JAK1·JAK2·JAK3·TYK2
Associated Conditions
myelofibrosis·alopecia areata·kidney disease·acute myeloid leukemia·head and neck squamous cell carcinoma·
* The information provided here is compiled from public sources and is for reference only.
